{"id":47065,"date":"2025-11-12T22:36:17","date_gmt":"2025-11-12T14:36:17","guid":{"rendered":"https:\/\/flcube.com\/?p=47065"},"modified":"2025-11-12T22:36:18","modified_gmt":"2025-11-12T14:36:18","slug":"jinling-pharmaceutical-nanjing-gulou-hospital-and-cd16a-tech%e2%80%91transfer-deal-bolsters-nk%e2%80%91cell-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47065","title":{"rendered":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology"},"content":{"rendered":"\n<p><strong>Jinling Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000919:SHE\">SHE: 000919<\/a>) today announced a strategic technology transfer agreement with <strong>Nanjing Gulou Hospital<\/strong>. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen <strong>CD16a<\/strong> and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is <strong>RMB\u202f78.5\u202fmillion<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-transaction-highlights\">Transaction Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Jinling Pharmaceutical &amp; Nanjing\u202fGulou Hospital<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>CD16a\u2011targeted NK\u2011cell cell adaptor, enabling antigen\u2011specific tumor killing without transfection<\/td><\/tr><tr><td><strong>Contract Value<\/strong><\/td><td>RMB\u202f78.5\u202fmillion (full payment)<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Jinling to lead research, scale\u2011up, and market the platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NK\u2011Cell Efficacy<\/strong> \u2013 The CD16a adaptor attaches directly to the anchoring protein on NK\u2011cell surfaces, amplifying their anti\u2011tumor response.<\/li>\n\n\n\n<li><strong>Speed to Market<\/strong> \u2013 The technology transfer eliminates the need for extensive in\u2011house R&amp;D, shortening the time from bench to clinic.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 The deal positions Jinling to broaden its oncology pipeline with a next\u2011generation immunotherapy platform.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u91d1\u9675\u836f\u4e1a\uff1a\u91d1\u9675\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u7b7e\u7f72\u6280\u672f\u8f6c\u8ba9\uff08\u6280\u672f\u79d8\u5bc6\uff09\u5408\u540c\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u91d1\u9675\u836f\u4e1a\uff1a\u91d1\u9675\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u7b7e\u7f72\u6280\u672f\u8f6c\u8ba9\uff08\u6280\u672f\u79d8\u5bc6\uff09\u5408\u540c\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-c9365a38-1abf-47f8-af88-4ae1552b6cc2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u91d1\u9675\u836f\u4e1a\uff1a\u91d1\u9675\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u7b7e\u7f72\u6280\u672f\u8f6c\u8ba9\uff08\u6280\u672f\u79d8\u5bc6\uff09\u5408\u540c\u7684\u516c\u544a.pdf\">\u91d1\u9675\u836f\u4e1a\uff1a\u91d1\u9675\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u7b7e\u7f72\u6280\u672f\u8f6c\u8ba9\uff08\u6280\u672f\u79d8\u5bc6\uff09\u5408\u540c\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u91d1\u9675\u836f\u4e1a\uff1a\u91d1\u9675\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u7b7e\u7f72\u6280\u672f\u8f6c\u8ba9\uff08\u6280\u672f\u79d8\u5bc6\uff09\u5408\u540c\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c9365a38-1abf-47f8-af88-4ae1552b6cc2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4454,4455],"class_list":["post-47065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-jinling-pharmaceutical","tag-she-000919"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47065\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology\" \/>\n<meta property=\"og:description\" content=\"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47065\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T14:36:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-12T14:36:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology\",\"datePublished\":\"2025-11-12T14:36:17+00:00\",\"dateModified\":\"2025-11-12T14:36:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1204-1.webp\",\"keywords\":[\"Cancer\",\"Jinling Pharmaceutical\",\"SHE: 000919\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47065#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47065\",\"name\":\"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1204-1.webp\",\"datePublished\":\"2025-11-12T14:36:17+00:00\",\"dateModified\":\"2025-11-12T14:36:18+00:00\",\"description\":\"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47065\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1204-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1204-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47065#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology - Insight, China&#039;s Pharmaceutical Industry","description":"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47065","og_locale":"en_US","og_type":"article","og_title":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology","og_description":"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.","og_url":"https:\/\/flcube.com\/?p=47065","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T14:36:17+00:00","article_modified_time":"2025-11-12T14:36:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47065#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47065"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology","datePublished":"2025-11-12T14:36:17+00:00","dateModified":"2025-11-12T14:36:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47065"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","keywords":["Cancer","Jinling Pharmaceutical","SHE: 000919"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47065#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47065","url":"https:\/\/flcube.com\/?p=47065","name":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47065#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","datePublished":"2025-11-12T14:36:17+00:00","dateModified":"2025-11-12T14:36:18+00:00","description":"Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK\u2011cell\u2013specific antigen CD16a and its tumor\u2011specific antigen cell\u2011adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB\u202f78.5\u202fmillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47065#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47065"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47065#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","width":1080,"height":608,"caption":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47065#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jinling Pharmaceutical, Nanjing\u202fGulou Hospital, and CD16a Tech\u2011Transfer Deal Bolsters NK\u2011Cell Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1204-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47065"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47065\/revisions"}],"predecessor-version":[{"id":47078,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47065\/revisions\/47078"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47077"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}